Introduction Vitiligo pathogenesis is complicated, and several possibilities were suggested. However, it is well-known that the metabolism of pigments plays a significant role in the pathogenicity of the disease. Objectives We explored the role of amino acids in vitiligo using targeted metabolomics. Methods The amino acid profile was studied in plasma using liquid chromatography. First, 22 amino acids were derivatized and precisely determined. Next, the concentrations of the amino acids and the molar ratios were calculated in 31 patients and 34 healthy individuals. Results The differential concentrations of amino acids were analyzed and eight amino acids, i.e., cysteine, arginine, lysine, ornithine, proline, glutamic acid, histidine, and glycine were observed differentially. The ratios of cysteine, glutamic acid, and proline increased significantly in Vitiligo patients, whereas arginine, lysine, ornithine, glycine, and histidine decreased significantly compared to healthy individuals. Considering the percentage of skin area, we also showed that glutamic acid significantly has a higher amount in patients with less than 25% involvement compared to others. Finally, cysteine and lysine are considered promising candidates for diagnosing and developing the disorder with high accuracy (0.96). Conclusion The findings are consistent with the previously illustrated mechanism of Vitiligo, such as production deficiency in melanin and an increase in immune activity and oxidative stress. Furthermore, new evidence was provided by using amino acids profile toward the pathogenicity of the disorder.

Adenoid cystic carcinoma (ACC) is a slow-growing malignancy that most often occurs in the salivary glands. Although reasonable local control is usually achieved by tumor surgery and subsequent radiation therapy, recurrence at the same or distant site is the cause of treatment failure. Currently, no FDA-approved therapeutic target or diagnostic biomarker has been identified for this cancer. To find the therapeutic and diagnostic targets for ACC, we extracted the gene expression information from two GEO datasets. Different expression genes (DEGs) between ACC and normal samples were extracted and used to explore the biochemical pathways involved in ACC and create a protein-protein interaction (PPI) network.After analyzing the PPI network, 20 hub genes were introduced that have potential as diagnostic and therapeutic target. Among them, PLCG1 and EZH2 were introduced as new biomarkers in ACC that might have a high value in the diagnosis and treatment of ACC. Furthermore, by studying the roles of the hub genes in the enriched biochemical pathways, we found that most likely, IGF-1R/IR and PPARG pathways play a critical role in tumorigenesis and drug resistance in the ACC and have a high potential for selection as a therapeutic target in future studies.

Adenoid cystic carcinoma (ACC) is a slow-growing malignancy that most often occurs in the salivary glands. Although reasonable local control is usually achieved by tumor surgery and subsequent radiation therapy, recurrence at the same or distant site is the cause of treatment failure. Currently, no FDA-approved therapeutic target or diagnostic biomarker has been identified for this cancer. To find the therapeutic and diagnostic targets for ACC, we extracted the gene expression information from two GEO datasets. Different expression genes (DEGs) between ACC and normal samples were extracted and used to explore the biochemical pathways involved in ACC and create a protein-protein interaction (PPI) network.After analyzing the PPI network, 20 hub genes were introduced that have potential as diagnostic and therapeutic target. Among them, PLCG1 and EZH2 were introduced as new biomarkers in ACC that might have a high value in the diagnosis and treatment of ACC. Furthermore, by studying the roles of the hub genes in the enriched biochemical pathways, we found that most likely, IGF-1R/IR and PPARG pathways play a critical role in tumorigenesis and drug resistance in the ACC and have a high potential for selection as a therapeutic target in future studies.

No abstract